Additional file 1: Appendix 1. of A comparison of generic drug prices in seven European countries: a methodological analysis

Additional file 1: of Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Y. Bazargani (3580277)
M. Ugurlu (5448896)
A. de Boer (3580283)
H. Leufkens (3580280)
A. Mantel-Teeuwisse (5448893)

June 2018

Overview of the countries included in the study. Including country names, World Bank income level, W...

Additional file 1: Table S1. of Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward

Dimitra Panteli (3552680)
Alexandra Nolting (3552686)
Helene Eckhardt (3552689)
Michael Kulig (229242)
Reinhard Busse (3552683)

January 2016

Overview of information per institution and domain (and list of alternative institutions contacted)....

Additional file 9: TableÂ S7. of Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs

Muhammad Hammami (3403061)
Sophia De Padua (4671400)
Rajaa Hussein (4671406)
Eman Al Gaai (3403058)
Nesrine Khodr (4671397)
Reem Al-Swayeh (4671403)
Syed Alvi (4671409)
Nada Binhashim (4671412)

December 2017

Average bioequivalence of 72-h-truncated area-under-the-concentration-time curve among three randoml...

Additional file 1: Appendix 1. of Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study

Chien-Wen Tseng (86520)
Grace Lin (91012)
James Davis (2267599)
Deborah Taira (3428795)
Jinoos Yazdany (843575)
Qimei He (73656)
Randi Chen (560898)
Allison Imamura (3428792)
R. Dudley (3428789)

September 2016

BASELINE medication use and cost in 2007 – Means and standard deviations. Baseline medication use an...

Additional file 1: of From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

Dimitra Panteli (3552680)
Helene Eckhardt (3552689)
Alexandra Nolting (3552686)
Reinhard Busse (3552683)
Michael Kulig (229242)

September 2015

Overview of comparative peer-reviewed publications on elements of reimbursement and pricing. (PDF 29...

Additional file 4: Table S1. of From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

Dimitra Panteli (3552680)
Helene Eckhardt (3552689)
Alexandra Nolting (3552686)
Reinhard Busse (3552683)
Michael Kulig (229242)

September 2015

Overview of evidence-based decision-making processes for pharmaceutical coverage in 36 countries. (D...

Additional file 2: of Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011â2013

Sohyun Jeong (3712729)
Minji Sohn (4166143)
Jae Kim (2100565)
Minoh Ko (4166134)
Hee-won Seo (4166149)
Yun-Kyoung Song (4166146)
Boyoon Choi (4166137)
Nayoung Han (3949715)
Han-Sung Na (4166140)
Jong Lee (3448640)
In-Wha Kim (711438)
Jung Oh (3454469)
Euni Lee (822530)

June 2017

The geographical distribution and characteristics of drug interventional clinical trial in the top 3...

Additional file 1: of Comparing access to orphan medicinal products in Europe

Bernarda Zamora (6664958)
Francois Maignen (6664961)
Phill OâNeill (6664964)
Jorge Mestre-Ferrandiz (3421655)
Martina Garau (6664967)

May 2019

Presents a table with the list of 143 OMPs with relevant EC authorisation data matched with a reimbu...

Additional file 1: of An anticholinergic burden score for German prescribers: score development

Esther Kiesel (5845730)
Yvonne Hopf (5845733)
Michael Drey (5845736)

October 2018

Table S1. Drugs extracted from published tools and excluded because they are not available in German...

Additional file 3: of Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice – the ECSTATIC study: a cluster randomised non-inferiority trial

Clare Luymes (4753356)
Rosalinde Poortvliet (3717631)
Nan van Geloven (185707)
Margot de Waal (4753353)
Yvonne Drewes (4753359)
Jeanet Blom (601800)
Nynke Smidt (791302)
Willem Assendelft (3475136)
Wilbert van den Hout (4753350)
Wouter de Ruijter (293035)
Mattijs Numans (3543974)

January 2018

Cost-effectiveness analysis. Table S2. Costs (in £) for the preparation of the intervention, per sel...

Additional file 1: of Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

A. Sicras-Mainar (6059510)
L. Sánchez-Álvarez (6059513)
R. Navarro-Artieda (6059516)
J. Darbà (6059519)

December 2018

Table S1. Sociodemographic and comorbidities at start of treatment comparing brand-name vs. generic ...

Additional file 1: of Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)

Uwe Koppe (5338451)
Anja von Laer (5168072)
Lars Kroll (4091710)
Ines Noll (5338454)
Marcel Feig (213466)
Marc Schneider (2103364)
Hermann Claus (255836)
Tim Eckmanns (202473)
Muna Abu Sin (569712)

June 2018

Appendix S1. List of laboratories that participate in ARS and contributed data to this analysis. App...

Additional file 1: of Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

Giuseppe Roberto (3139791)
Francesco Barone-Adesi (355270)
Francesco Giorgianni (523751)
Valeria Pizzimenti (6314552)
Carmen Ferrajolo (605704)
Michele Tari (5893799)
Claudia Bartolini (6314555)
Roberto Da Cas (433997)
Marina Maggini (275336)
Stefania Spila-Alegiani (357034)
Paolo Francesconi (535541)
Gianluca TrifirĂ˛ (6314561)
Elisabetta Poluzzi (487411)
Fabio Baccetti (6314558)
Rosa Gini (451348)

February 2019

Appendix 1. Antidiabetic drugs of interest for the study, as available in Italy during the observati...

Additional file 1: of The European challenges of funding orphan medicinal products

Márta Szegedi (3412340)
Tamás Zelei (3412334)
Francis Arickx (5933423)
Anna Bucsics (5933426)
Emanuelle Cohn-Zanchetta (5933429)
Jurij Fürst (4723815)
Maria Kamusheva (5772647)
Pawel Kawalec (5933432)
Guenka Petrova (4723785)
Juraj Slaby (5933435)
Ewa Stawowczyk (30350)
Milan Vocelka (5933438)
Ingrid Zechmeister-Koss (5933441)
Zoltán Kaló (832396)
Mária Molnár (3412337)

November 2018

The Map for Funding Orphan Medicinal Products in 8 EU Member States in 2015. (DOCX 63 kb

Additional file 4: of Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims

Maria Wertli (3210867)
Oliver Reich (618300)
Andri Signorell (696242)
Jakob Burgstaller (3799819)
Johann Steurer (5157)
Ulrike Held (20101)

February 2017

Geographical variation in increase of the use of strong opioids between 2006 and 2013 and variation ...

Additional file 1: of Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Y. Bazargani (3580277)
M. Ugurlu (5448896)
A. de Boer (3580283)
H. Leufkens (3580280)
A. Mantel-Teeuwisse (5448893)

June 2018

Overview of the countries included in the study. Including country names, World Bank income level, W...

Additional file 1: Table S1. of Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward

Dimitra Panteli (3552680)
Alexandra Nolting (3552686)
Helene Eckhardt (3552689)
Michael Kulig (229242)
Reinhard Busse (3552683)

January 2016

Overview of information per institution and domain (and list of alternative institutions contacted)....

Additional file 9: TableÂ S7. of Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs

Muhammad Hammami (3403061)
Sophia De Padua (4671400)
Rajaa Hussein (4671406)
Eman Al Gaai (3403058)
Nesrine Khodr (4671397)
Reem Al-Swayeh (4671403)
Syed Alvi (4671409)
Nada Binhashim (4671412)

December 2017

Average bioequivalence of 72-h-truncated area-under-the-concentration-time curve among three randoml...

Additional file 1: Appendix 1. of Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study

Chien-Wen Tseng (86520)
Grace Lin (91012)
James Davis (2267599)
Deborah Taira (3428795)
Jinoos Yazdany (843575)
Qimei He (73656)
Randi Chen (560898)
Allison Imamura (3428792)
R. Dudley (3428789)

September 2016

BASELINE medication use and cost in 2007 – Means and standard deviations. Baseline medication use an...

Additional file 1: of From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

Dimitra Panteli (3552680)
Helene Eckhardt (3552689)
Alexandra Nolting (3552686)
Reinhard Busse (3552683)
Michael Kulig (229242)

September 2015

Overview of comparative peer-reviewed publications on elements of reimbursement and pricing. (PDF 29...

Additional file 4: Table S1. of From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries

Dimitra Panteli (3552680)
Helene Eckhardt (3552689)
Alexandra Nolting (3552686)
Reinhard Busse (3552683)
Michael Kulig (229242)

September 2015

Overview of evidence-based decision-making processes for pharmaceutical coverage in 36 countries. (D...

Additional file 2: of Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011â2013

Sohyun Jeong (3712729)
Minji Sohn (4166143)
Jae Kim (2100565)
Minoh Ko (4166134)
Hee-won Seo (4166149)
Yun-Kyoung Song (4166146)
Boyoon Choi (4166137)
Nayoung Han (3949715)
Han-Sung Na (4166140)
Jong Lee (3448640)
In-Wha Kim (711438)
Jung Oh (3454469)
Euni Lee (822530)

June 2017

The geographical distribution and characteristics of drug interventional clinical trial in the top 3...

Additional file 1: of Comparing access to orphan medicinal products in Europe

Bernarda Zamora (6664958)
Francois Maignen (6664961)
Phill OâNeill (6664964)
Jorge Mestre-Ferrandiz (3421655)
Martina Garau (6664967)

May 2019

Presents a table with the list of 143 OMPs with relevant EC authorisation data matched with a reimbu...

Additional file 1: of An anticholinergic burden score for German prescribers: score development

Esther Kiesel (5845730)
Yvonne Hopf (5845733)
Michael Drey (5845736)

October 2018

Table S1. Drugs extracted from published tools and excluded because they are not available in German...

Additional file 3: of Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice – the ECSTATIC study: a cluster randomised non-inferiority trial

Clare Luymes (4753356)
Rosalinde Poortvliet (3717631)
Nan van Geloven (185707)
Margot de Waal (4753353)
Yvonne Drewes (4753359)
Jeanet Blom (601800)
Nynke Smidt (791302)
Willem Assendelft (3475136)
Wilbert van den Hout (4753350)
Wouter de Ruijter (293035)
Mattijs Numans (3543974)

January 2018

Cost-effectiveness analysis. Table S2. Costs (in £) for the preparation of the intervention, per sel...

Additional file 1: of Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis

A. Sicras-Mainar (6059510)
L. Sánchez-Álvarez (6059513)
R. Navarro-Artieda (6059516)
J. Darbà (6059519)

December 2018

Table S1. Sociodemographic and comorbidities at start of treatment comparing brand-name vs. generic ...

Additional file 1: of Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)

Uwe Koppe (5338451)
Anja von Laer (5168072)
Lars Kroll (4091710)
Ines Noll (5338454)
Marcel Feig (213466)
Marc Schneider (2103364)
Hermann Claus (255836)
Tim Eckmanns (202473)
Muna Abu Sin (569712)

June 2018

Appendix S1. List of laboratories that participate in ARS and contributed data to this analysis. App...

Additional file 1: of Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas

Giuseppe Roberto (3139791)
Francesco Barone-Adesi (355270)
Francesco Giorgianni (523751)
Valeria Pizzimenti (6314552)
Carmen Ferrajolo (605704)
Michele Tari (5893799)
Claudia Bartolini (6314555)
Roberto Da Cas (433997)
Marina Maggini (275336)
Stefania Spila-Alegiani (357034)
Paolo Francesconi (535541)
Gianluca TrifirĂ˛ (6314561)
Elisabetta Poluzzi (487411)
Fabio Baccetti (6314558)
Rosa Gini (451348)

February 2019

Appendix 1. Antidiabetic drugs of interest for the study, as available in Italy during the observati...

Additional file 1: of The European challenges of funding orphan medicinal products

Márta Szegedi (3412340)
Tamás Zelei (3412334)
Francis Arickx (5933423)
Anna Bucsics (5933426)
Emanuelle Cohn-Zanchetta (5933429)
Jurij Fürst (4723815)
Maria Kamusheva (5772647)
Pawel Kawalec (5933432)
Guenka Petrova (4723785)
Juraj Slaby (5933435)
Ewa Stawowczyk (30350)
Milan Vocelka (5933438)
Ingrid Zechmeister-Koss (5933441)
Zoltán Kaló (832396)
Mária Molnár (3412337)

November 2018

The Map for Funding Orphan Medicinal Products in 8 EU Member States in 2015. (DOCX 63 kb

Additional file 4: of Changes over time in prescription practices of pain medications in Switzerland between 2006 and 2013: an analysis of insurance claims

Maria Wertli (3210867)
Oliver Reich (618300)
Andri Signorell (696242)
Jakob Burgstaller (3799819)
Johann Steurer (5157)
Ulrike Held (20101)

February 2017

Geographical variation in increase of the use of strong opioids between 2006 and 2013 and variation ...

Additional file 1: of Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Y. Bazargani (3580277)
M. Ugurlu (5448896)
A. de Boer (3580283)
H. Leufkens (3580280)
A. Mantel-Teeuwisse (5448893)

June 2018

Overview of the countries included in the study. Including country names, World Bank income level, W...

Additional file 1: Table S1. of Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward

Dimitra Panteli (3552680)
Alexandra Nolting (3552686)
Helene Eckhardt (3552689)
Michael Kulig (229242)
Reinhard Busse (3552683)

January 2016

Overview of information per institution and domain (and list of alternative institutions contacted)....

Additional file 9: TableÂ S7. of Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs

Muhammad Hammami (3403061)
Sophia De Padua (4671400)
Rajaa Hussein (4671406)
Eman Al Gaai (3403058)
Nesrine Khodr (4671397)
Reem Al-Swayeh (4671403)
Syed Alvi (4671409)
Nada Binhashim (4671412)

December 2017

Average bioequivalence of 72-h-truncated area-under-the-concentration-time curve among three randoml...

Additional file 1: Appendix 1. of A comparison of generic drug prices in seven European countries: a methodological analysis

Abstract

Extracted data

Additional file 1: Appendix 1. of A comparison of generic drug prices in seven European countries: a methodological analysis

Abstract

Extracted data

Related items

Related items